Apellis Pharmaceuticals Inc Année d'introduction en bourse
Quel est le Année d'introduction en bourse de Apellis Pharmaceuticals Inc?
Le Année d'introduction en bourse de Apellis Pharmaceuticals Inc est 1970
Quelle est la définition de Année d'introduction en bourse?
Le premier appel public à l'épargne est un type d'offre publique dans lequel les actions d'une entreprise sont généralement vendues à des investisseurs institutionnels qui, pour leur part, vendent au grand public, pour la première fois, sur une bourse de valeurs.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Année d'introduction en bourse des entreprises dans Health Care secteur sur NASDAQ par rapport à Apellis Pharmaceuticals Inc
Que fait Apellis Pharmaceuticals Inc?
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Entreprises avec année d'introduction en bourse similaire à Apellis Pharmaceuticals Inc
- Vanguard FTSE Developed Europe ex UK ETF a Année d'introduction en bourse de 1969
- Apellis Pharmaceuticals Inc a Année d'introduction en bourse de 1970
- PepsiCo Inc a Année d'introduction en bourse de 1972
- Applied Materials a Année d'introduction en bourse de 1972
- L&T Finance a Année d'introduction en bourse de 1972
- Coca-Cola Consolidated Inc a Année d'introduction en bourse de 1972
- GT Biopharma a Année d'introduction en bourse de 1972
- Jacobs Solutions Inc a Année d'introduction en bourse de 1972